DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
TEVA logo

Teva Pharmaceutical Industries Limited Stock Price

NYSE:TEVA Community·US$42.8b Market Cap
  • 3 Narratives written by author
  • 2 Comments on narratives written by author
  • 126 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

TEVA Share Price Performance

US$36.85
17.28 (88.30%)
​
US$41.91
Fair Value
US$36.85
17.28 (88.30%)
12.1% undervalued intrinsic discount
US$41.91
Fair Value
Price US$36.85
AnalystConsensusTarget US$41.91
AnalystHighTarget US$48.72
AnalystLowTarget US$33.08
Wed, 9 Sep 26
Fair ValueUS$41.91
Share Pricen/a

TEVA Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$41.91 12.1% undervalued intrinsic discount

Analyst Commentary Highlights Modest Price Target Increase and Positive Outlook for Teva Pharmaceutical Industries

1users have liked this narrative
2users have commented on this narrative
55users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$48.72 24.4% undervalued intrinsic discount

Late Stage Pipeline And Margin Expansion Will Transform This Pharma Into A Future Cash Engine

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$33.08 11.4% overvalued intrinsic discount

Late Stage Pipeline And Biosimilar Pressure Will Constrain Long Term Earnings Power

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
TEVA logo
Teva Pharmaceutical Industries
12.1% undervalued intrinsic discount
Updated

Analyst Commentary Highlights Modest Price Target Increase and Positive Outlook for Teva Pharmaceutical Industries

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 9 Sep
Read Narrative
TEVA logo
Teva Pharmaceutical Industries
11.4% overvalued intrinsic discount

Late Stage Pipeline And Biosimilar Pressure Will Constrain Long Term Earnings Power

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 21 Jul
Read Narrative
TEVA logo
Teva Pharmaceutical Industries
24.4% undervalued intrinsic discount

Late Stage Pipeline And Margin Expansion Will Transform This Pharma Into A Future Cash Engine

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 7 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
TEVA logo

TEVA: Celiac And Vitiligo Data Are Expected To Drive Neuroscience Pivot

Fair Value: US$41.91 12.1% undervalued intrinsic discount
55 fair values setusers have set this as their fair value
2 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
TEVA logo

TEVA: Fairly Valued Outlook Will Weigh Vitiligo Data And Biosimilar Expansion

Fair Value: US$33.08 11.4% overvalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
AN
AnalystHighTarget
TEVA logo

TEVA: Vitiligo Readout And Neuroscience Expansion Are Expected To Drive Upside

Fair Value: US$48.72 24.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Reasonable growth potential and slightly overvalued.

2 Risks
3 Rewards
View Full Analysis

Teva Pharmaceutical Industries Limited Key Details

US$17.3b

Revenue

US$8.2b

Cost of Revenue

US$9.1b

Gross Profit

US$8.4b

Other Expenses

US$706.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.61
52.46%
4.08%
214.2%
View Full Analysis

About TEVA

Founded
1901
Employees
32008
CEO
Richard Francis
WebsiteView website
www.tevapharm.com

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Recent TEVA News & Updates

Recent updates

No updates

Teva Pharmaceutical Industries Limited Competitors

TMO logo

Thermo Fisher Scientific

Symbol: NYSE:TMO
Market cap: US$223.0b
AMGN logo

Amgen

Symbol: NasdaqGS:AMGN
Market cap: US$212.6b
GILD logo

Gilead Sciences

Symbol: NasdaqGS:GILD
Market cap: US$181.8b
PFE logo

Pfizer

Symbol: NYSE:PFE
Market cap: US$158.4b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide